Dr. Richter on the Importance of Optimizing Available Therapies in Multiple Myeloma | OncLive

Dr. Richter on the Importance of Optimizing Available Therapies in Multiple Myeloma

September 2, 2020

Partner | Cancer Centers

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma. 

Joshua Richter, MD, an assistant professor of medicine, and a hematologist/oncologist at Mount Sinai Hospital, discusses the importance of optimizing available therapies in multiple myeloma. 

Historically, multiple myeloma was thought to be an incurable disease, says Richter. ​However, ​multiple advances in the field have pushed the field closer to developing a cure for patients.  

In addition to conducting more clinical trials and evaluating novel regimens, it is necessary to optimize available therapies, Richter adds. 

Utilizing a multiomic approach may allow the field to optimize existing approaches, ​and provide precision medicine to patients with multiple myeloma, Richter concludes. 


x